This policy watch examines the likely impact of an executive order signed by President Trump in July 2020 related to prescription drugs, which would use lower international drug prices to set prices for a limited set of drugs in the U.S.
Most People Are Unlikely to See Drug Cost Savings From President Trump’s “Most Favored Nation” Proposal
